Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2022 | Genomic determinants of response to blinatumomab

Yaqi Zhao • 11 Apr 2022
AACR 2022
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab

In this video, Yaqi Zhao, MSc, St. Jude Children’s Research Hospital, Memphis, TN, discusses the genomic determinants of response to blinatumomab in patients with B-cell acute lymphoblastic leukemia (B-ALL). Ms Zhao explains a study which found that blinatumomab resistance is associated with deleterious mutations in CD22, and that patients with the high-risk (Ph)-like subtype have a superior response rate to blinatumomab. Ms Zhao also briefly discusses a recent study analyzing bone marrow samples from 4 patients with B-ALL which found that resistance to blinatumomab is associated with T cell exhaustion. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.

More from Yaqi Zhao

Novel targeted antibodies for R/R B-ALL
0:47
Novel targeted antibodies for R/R B-ALL
Yaqi Zhao • 11 Apr 2022
Update on the INO-VATE trial: inotuzumab vs chemotherapy for ALL
1:59
Update on the INO-VATE trial: inotuzumab vs chemotherapy for ALL
Yaqi Zhao • 11 Apr 2022

Related Videos

Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
1:21
Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
Marco Ruella • 16 Oct 2026
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
1:45
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
Celso Arrais • 17 Oct 2026
Insights into the current CLL treatment algorithm and emerging research directions
1:51
Insights into the current CLL treatment algorithm and emerging research directions
Matthew Davids • 17 Oct 2026
How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
1:21
How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
Richard Rosenquist • 17 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals